The effect of COVID-19 on absolute neutrophil counts in patients taking clozapine

Siobhan Gee and David Taylor

Abstract
Clozapine is associated with haematological side effects, including neutropenia, which can signal impending life-threatening agranulocytosis. Patients with COVID-19 infection frequently experience lymphopenia, but not neutropenia. We present 13 patients established on clozapine who developed COVID-19 infection. There were no significant differences in total white cell or neutrophil counts between pre-COVID-19, intra-COVID-19 or post-COVID-19 periods. We therefore suggest that patients who develop COVID-19 should generally have their clozapine treatment continued. Patients taking clozapine who develop neutropenia during COVID-19 infection should be investigated and monitored as in normal practice, because changes in neutrophil counts cannot be assumed to be due to the viral infection.

Keywords: clozapine, coronavirus, COVID-19, schizophrenia, agranulocytosis, neutropenia

Introduction
Clozapine has known haematological side effects. The most common (2.7% of patients) is neutropenia, which can sometimes portend life-threatening agranulocytosis (0.4% of patients). For this reason, monitoring of the WCC [including absolute neutrophil count (ANC)] is mandatory in many countries. Over 80% of cases of agranulocytosis occur in the first 18 weeks of treatment. By the end of the first year of treatment, the risk of agranulocytosis is comparable with that of other antipsychotics. Neutrophil counts of 0.5–1.5 × 10⁹/l (mild-to-moderate neutropenia) are not associated with a significantly increased risk of infection. Agranulocytosis in this context is defined as neutrophil counts of <0.5 × 10⁹/l, where the case fatality rate is between 2% and 4%.

Current data suggest that COVID-19 infection results in a lowered white cell count (WCC) of <4.0 × 10⁹/l for between 9 and 45% of patients. Lymphocytopenia (lymphocytes <1.5 × 10⁹/l) is especially common, being reported in 33–83% of patients. More severe abnormalities correlate with severity of the disease; lower counts are seen in those for whom infection is fatal. In contrast, studies in COVID-19 patients have found neutrophils to be in the normal range (3.0–7.5 × 10⁹/l). There are no published data describing neutrophil counts in COVID-19-positive patients taking clozapine.

We present a series of patients who contracted COVID-19 whilst taking clozapine. Neutrophil counts and WCCs are illustrated for the period prior to contracting COVID-19, during the infection, and after recovery.

Method
All patients were either inpatients at South London and the Maudsley NHS Foundation Trust at the time of testing positive for COVID-19 or admitted to the neighbouring acute trust and were under the care of the psychiatric liaison team. The ANC taken a minimum of 14 days prior to a positive nasopharyngeal swab for viral ribonucleic acid of SARS-CoV-2 was used as a ‘baseline’ ANC level. The day of the positive COVID-19 swab was designated as day 0.

The effect of COVID-19 on absolute neutrophil counts in patients taking clozapine

Siobhan Gee and David Taylor

Abstract
Clozapine is associated with haematological side effects, including neutropenia, which can signal impending life-threatening agranulocytosis. Patients with COVID-19 infection frequently experience lymphopenia, but not neutropenia. We present 13 patients established on clozapine who developed COVID-19 infection. There were no significant differences in total white cell or neutrophil counts between pre-COVID-19, intra-COVID-19 or post-COVID-19 periods. We therefore suggest that patients who develop COVID-19 should generally have their clozapine treatment continued. Patients taking clozapine who develop neutropenia during COVID-19 infection should be investigated and monitored as in normal practice, because changes in neutrophil counts cannot be assumed to be due to the viral infection.

Keywords: clozapine, coronavirus, COVID-19, schizophrenia, agranulocytosis, neutropenia

Received: 21 May 2020; revised manuscript accepted: 15 June 2020.
mean ANCs and WCCs for days 0–7 and days 8–14 are reported. Data were analysed using IBM SPSS Statistics 26 (IBM Corp., Armonk, NY, USA) and means compared using paired samples t-tests. Approval for this study was granted by the trust’s drug and therapeutics committee.

Results
Data for 13 consecutive patients (9 female, 4 male) are presented (Table 1). The mean age was 48 years at the time of the positive swab, and nine patients were of non-White background. All except two patients had their regular clozapine full blood count taken monthly and had therefore been taking clozapine for more than a year. Two had a prior diagnosis of benign ethnic neutropae- nia (BEN).

The mean ANC at baseline was $4.83 \times 10^9$, reducing to $4.24 \times 10^9$ in the first week following a positive COVID-19 swab (Table 2). Mean ANC for the second week was $5.70 \times 10^9$. No ANC was taken in the time period between days 8 and 14 for one patient; the next available ANC was used as representative of the post-infection ANC count. Three patients died in the week after testing positive; their data are included in the baseline and week 1 mean ANC but missing for week 2. Two of the patients that died were women, two were of non-White heritage and one had a BEN diagnosis. All had been on clozapine for more than a year. The mean age at death was 65 years. Medical comorbidities are outlined in Table 2. The cause of death was given as COVID-19 pneumonia in two cases, and myocardial infarction in the third.

There were no statistically significant differences between mean ANC at baseline and days 0–7 after the positive COVID-19 result ($p = 0.240$), between the mean ANC on days 0–7 and days 8–14 ($p = 0.155$), or between baseline ANC and mean ANC on days 8–14 ($p = 0.509$; Figure 1).

Discussion
This case series shows that no statistically significant change in ANC occurred in patients taking clozapine who tested positive for the novel coronavirus SARS-CoV-2. We observed no clear trend for reduction in neutrophil counts during infection. There are two major clinical implications. First, clozapine should generally be continued during coronavirus infection. Second, patients taking clozapine who experience neutropaenia whilst suffering from COVID-19 should be investigated and monitored as per normal practice, as it cannot be assumed to be secondary to the viral infection.

Viral infections, including influenza, commonly cause neutropaenia, either by suppressing bone marrow production or accelerating peripheral destruction. Data from the COVID-19 outbreak in China suggest that patients with COVID-19 infection frequently present with low WCC. This appears to be due to reduced lymphocytes. Lymphocytopenia in patients with COVID-19 is shown to be predictive of disease progression, correlating with high levels of interleukins 6 and 8 and a severe or critical clinical outcome. The increase in inflammatory cytokines causes a rise in neutrophils as part of the initial antiviral immune response.

The data we present here show no significant change in neutrophil counts but faintly suggest an initial small fall in neutrophil counts followed by a rise, in line with expected immune responses to viral infection. Clozapine-induced neutropaenia is an

| Table 1. Demographic characteristics of total sample. |
|-----------------|-----------------|
| **n (N=13)**    |                 |
| Mean age in years (range) | 48 (19–75) |
| Male            | 4               |
| Ethnicity       |                 |
| Black British   | 3               |
| Black and White | 1               |
| Nigerian        | 2               |
| Caribbean       | 2               |
| Indian/British Indian | 1     |
| White           | 4               |
| BEN diagnosis   | 2               |
| Frequency of clozapine FBC monitoring | |
| Weekly          | 1               |
| Fortnightly     | 1               |
| Monthly         | 11              |

BEN, benign ethnic neutropaenia; FBC, full blood count.
Table 2. Clinical details and mean ANC and WCC for each time period.

| Patient | Length of time on clozapine | BEN | Medical comorbidities                                                                 | Mean ANC (×10⁹) | Mean WCC (×10⁹) | Outcome |
|---------|----------------------------|-----|-------------------------------------------------------------------------------------|-----------------|------------------|---------|
|         |                             |     |                                                                                     | Baseline | Days 0–7 | Days 8–14+ | Baseline | Days 0–7 | Days 8–14+ |         |
| A       | >1 year                     | No  | None                                                                                 | 2.91     | 3.45    | 2.93      | 5.39     | 5.10    | 5.00      | Survived |
| B       | 0–18 weeks                  | No  | Postural tachycardia syndrome                                                        | 3.65     | 4.63    | 3.2       | 6.24     | 6.60    | 5.61      | Survived |
| C       | >1 year                     | Yes | None                                                                                 | 5.21     | 2.78    | 3.2       | 8.19     | 6.31    | 6.25      | Survived |
| D       | 18–52 weeks                 | No  | Microcytic anaemia                                                                   | 3.47     | 4.75    | 8.01      | 8.4      | 8.86    | 8.82      | Survived |
| E       | >1 year                     | No  | None                                                                                 | 2.56     | 2.54    | 2.89      | 4.8      | 3.80    | 5.19      | Survived |
| F       | >1 year                     | No  | Anaemia                                                                              | 2.49     | 1.48    | 1.89      | 6.5      | 4.95    | 5.71      | Survived |
| G       | >1 year                     | No  | Type 2 diabetes mellitus, hypertension, obesity                                      | 11.2     | 10.10   | 20.64     | 15.69    | 12.67   | 26.79     | Survived |
| H       | >1 year                     | Yes | Type 2 diabetes mellitus, chronic obstructive pulmonary disease, chronic anaemia and neutropaenia, essential thrombocytopenia, hypercholesterolaemia, gastro-oesophageal reflux disease, gout, hypertension | 2.37     | 1.60    | N/A       | 4.79     | 2.62    | N/A       | Died     |
| I       | >1 year                     | No  | Type 2 diabetes mellitus                                                             | 4.92     | 2.96    | 4.77      | 7.41     | 4.35    | 8.01      | Survived |
| J       | >1 year                     | No  | Type 2 diabetes mellitus, thalassemia, cataracts,                                   | 5.09     | 4.02    | 7.01      | 8.27     | 5.68    | 9.24      | Survived |
| K       | >1 year                     | No  | Type 2 diabetes mellitus, end-stage renal failure, thromboembolic disease, ileostomy  | 6.86     | 9.68    | N/A       | 8.98     | 11.80   | N/A       | Died     |
| L       | >1 year                     | No  | Type 2 diabetes mellitus, psoriatic arthropathy, overactive bladder                  | 7.2      | 3.31    | 3.45      | 9.2      | 4.80    | 4.75      | Survived |
| M       | >1 year                     | No  | Type 2 diabetes mellitus, chronic obstructive pulmonary disease, hypertension, hypothyroidism, osteoporosis | 4.9      | 3.78    | N/A       | 8.1      | 4.99    | N/A       | Died     |

Mean (×10⁹), (range)  
4.83 [2.37–11.20] | 4.24 [1.48–10.10] | 5.70 [1.89–20.64] | 7.84 [4.79–15.69] | 6.35 [2.62–12.67] | 8.54 [4.75–26.79]  
ANC, absolute neutrophil count; N/A, not available; WCC, white cell count.
idiosyncratic reaction, possibly mediated by direct binding of metabolites to neutrophils\(^1\) and is rare beyond the first 3 months of treatment. It therefore seems unlikely that taking clozapine would predispose patients to adverse haematological effects in viral infections, since the immune response of neutrophils to inflammatory cytokines is not affected. COVID-19 infection does not appear to cause a significant or prolonged neutropaenia in patients taking clozapine. Patients should therefore continue to receive clozapine and be assessed for the possibility of clozapine-induced neutropaenic sepsis if they present with fever, cough, myalgia, fatigue or shortness of breath,\(^1\) bearing in mind that this is an extremely rare event in patients who have been established on treatment for more than 3 months.

**Acknowledgements**
The authors would like to thank the staff in the pharmacy departments at South London and the Maudsley NHS Foundation Trust for their assistance in identifying patients for inclusion in this study.

**Conflict of interest statement**
The authors declare that there is no conflict of interest.

**Funding**
The authors received no financial support for the research, authorship, and/or publication of this article.

**Figure 1.** Change in mean ANC. No statistically significant differences between mean ANC at each time point. ANC, absolute neutrophil count; CI, confidence interval.

**ORCID iDs**
Siobhan Gee [https://orcid.org/0000-0003-1020-6777](https://orcid.org/0000-0003-1020-6777)
David Taylor [https://orcid.org/0000-0002-2557-1710](https://orcid.org/0000-0002-2557-1710)

**References**
1. Taylor DM, Young AH and Barnes TRE. The Maudsley prescribing guidelines in psychiatry. 13th ed. Hoboken, NJ: Wiley Blackwell, Vol. 13, 2018, pp.1–854.
2. Li XH, Zhong XM, Lu L, et al. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. *Psychol Med* 2020; 50: 583–594.
3. Bachmann CJ, Aagaard L, Bernardo M, et al. International trends in clozapine use: a study in 17 countries. *Acta Psychiatr Scand* 2017; 136: 37–51.
4. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis – incidence and risk factors in the United States. *N Engl J Med* 1993; 29: 162–167.
5. Schulte PFJ. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. *Ann Pharmacother* 2006; 40: 683–688.
6. Meyer N, Gee S, Whiskey E, et al. Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. *J Clin Psychiatry* 2015; 76: e1410–e1416.
7. Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. *Acta Psychiatr Scand* 2018; 138: 101–109.

8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 497–506.

9. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; 395: 507–513.

10. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395: 1054–1062.

11. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; 382: 1708–1720.

12. Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study. *Clin Infect Dis*. Epub ahead of print 29 February 2020. DOI: 10.1093/cid/ciaa199.

13. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020; 323: 1061–1069.

14. Munshi HG and Montgomery RB. Severe neutropenia: a diagnostic approach. *West J Med* 2000; 172: 248–252.

15. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. *Nature*. Epub ahead of print 20 May 2020. DOI: 10.1038/s41586-020-2355-0.

16. Galani IE and Andreakos E. Neutrophils in viral infections: current concepts and caveats. *J Leukoc Biol* 2015; 98: 557–564.

17. Rajagopal S. Clozapine, agranulocytosis, and benign ethnic neutropenia. *Postgrad Med J* 2005; 81: 545–546.

18. Gee S, Gaughran F, MacCabe J, et al. Management of clozapine treatment during the COVID-19 pandemic. *Ther Adv Psychopharmacol* 2020; 10: 2045125320928167.